Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

Confluent (NASDAQ:CFLT – Get Free Report)‘s stock had its “outperform” rating reissued by analysts at William Blair in a ...

Fintel reports that on March 17, 2025, William Blair initiated coverage of Butterfly Network (NYSE:BFLY) with a Outperform ...

Equities researchers at William Blair issued their Q1 2026 EPS estimates for shares of Science Applications International in ...

US President Donald Trump has imposed a 25 % tariff on Canada’s steel and aluminium and has threatened sweeping tariffs on ...

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

Analysts at William Blair lowered their Q1 2025 earnings estimates for Legend Biotech in a research report issued to clients ...

William Blair Emerg Mkts ex China Growth earns a Below Average Process Pillar rating. The process is strengthened by low costs across its parent firm's funds, whose fees rank in their respective ...